Literature DB >> 1460322

Serum erythropoietin titers in hematological malignancies and related diseases.

A Urabe1, K Mitani, K Yoshinaga, S Iki, M Yagisawa, Y Ohbayashi, F Takaku.   

Abstract

Serum erythropoietin (Epo) titers in patients with various hematological malignancies and related diseases were determined by radioimmunoassay. Serum Epo titer was inversely correlated with hemoglobin concentration in iron deficiency anemia, aplastic anemia, myelodysplastic syndromes (MDS), acute leukemia, malignant lymphoma, multiple myeloma and myelofibrosis, but there was no correlation between serum Epo titer and hemoglobin concentration in chronic myelogenous leukemia or polycythemias. Serum Epo titers in aplastic anemia were much higher than those in iron deficiency anemia. Serum Epo titers in MDS, malignant lymphoma and multiple myeloma differed considerably among patients. Serum Epo titers in untreated polycythemia vera were significantly lower than in treated polycythemia vera or secondary polycythemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460322     DOI: 10.1002/stem.5530100604

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  5 in total

1.  Erythropoietin response is inadequate in cancer patients receiving chemotherapy.

Authors:  S J Lee; J H Kwon; C W Jung
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes.

Authors:  Takahiro Suzuki; Iekuni Oh; Ken Ohmine; Akiko Meguro; Masaki Mori; Shin-ichiro Fujiwara; Chihiro Yamamoto; Tadashi Nagai; Keiya Ozawa
Journal:  Int J Hematol       Date:  2014-11-06       Impact factor: 2.490

Review 3.  Inadequate erythropoietin response to anemia: definition and clinical relevance.

Authors:  G Barosi
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

Review 4.  Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

Authors:  Danielle M Townsley; Ronan Desmond; Cynthia E Dunbar; Neal S Young
Journal:  Int J Hematol       Date:  2013-05-21       Impact factor: 2.490

5.  Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.

Authors:  Kumi Nakazaki; Yasuhito Nannya; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-12-05       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.